Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
ZYME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.97 - $17.70
Previous CloseN/A
Volume35.38K
Average Volume (3M)382.89K
Market Cap
$1.02B
Enterprise Value$678.46M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Mar 05, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding68,877,525
10 Day Avg. Volume336,911
30 Day Avg. Volume382,886
Standard Deviation0.15
R-Squared0.14
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.25
Price to Cash Flow (P/CF)-43.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.13
Enterprise Value/Ebitda-6.22
Forecast
1Y Price Target
$20.25Price Target Upside36.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Zymeworks News
PremiumCompany Announcements
Zymeworks Welcomes Oleg Nodelman to Board of Directors
PremiumCompany Announcements
Zymeworks to Announce 2024 Financial Results and Host Corporate Update
PremiumCompany Announcements
Zymeworks to Engage Investors at Key Conferences
---
Bulls Say, Bears Say
Bulls Say
Financial MilestonesZYME will receive a $25 million regulatory milestone from its partner Jazz Pharmaceuticals.
Pipeline ExpansionZYME announced the 5th asset in the company's 5 by 5 solid tumor strategy, expanding into hematology/oncology and autoimmune and inflammatory diseases.
Regulatory ApprovalThe FDA granted accelerated approval to Ziihera (zanidatamab) in pre-treated HER2+ biliary tract cancer patients, which was widely anticipated.
Bears Say
Clinical Trial RisksRisks include clinical trial failures due to safety issues and clinical setbacks due to insufficient efficacy.
Market ValuationThe analyst reiterates a Neutral rating and views Zymeworks as fairly valued given the current share price.
---
Ownership Overview
22.79% Insiders
8.17% Mutual Funds
1.06% Other Institutional Investors
53.39% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $7.97 and its highest was $17.70 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is $1.02B.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Mar 05, 2025 which is in 12 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Oct 31, 2024. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.007.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -0.1.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 68,877,525 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went down -3.066%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in ZYME
---
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.25 (36.64% Upside)
$20.25 (36.64% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $14.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.29%
12-Months-Change
Fundamentals
Return on Equity
-28.73%
Trailing 12-Months
Asset Growth
-12.44%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
---
ZYME Company Deck
---
ZYME Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with significant advancements in clinical and preclinical developments, strategic partnerships, and financial management, but also highlighted challenges such as decreased revenue and cash reserves, and a substantial impairment charge.Read More>---
ZYME Stock 12 Month Forecast
Average Price Target
$20.25
▲(36.64% Upside)
Technical Analysis
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+42.87%
assigned a buy rating 4 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +42.87% per trade.
---